Synbiotic Therapy Improves Quality of Life and Reduces Symptoms in Pediatric Ulcerative Colitis

ICAN: Infant, Child, & Adolescent Nutrition

Volumn 1, Issue 2, 2009, Pages 88-93

  Haskey, Natasha ^a   Dahl, Wendy J ^b  

^a SASKATOON HEALTH REGION   (Canada)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

adolescent teen; early life span nutrition; gastrointestinal disorders; pre and probiotic therapy

Indexed keywords

EID: 84998183111     PISSN: 19414064     EISSN: None     Source Type: Journal    
DOI: 10.1177/1941406409332930     Document Type: Article

References (15)

1. Friedman S., Blumberg R. Inflammatory bowel disease. In: Kasper D, Fauci A, Longo D, et al, eds. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill; 2005: 1776–1789.
2. Cummings JH, Macfarlane GT, Macfarlane S. Intestinal bacteria and ulcerative colitis. Curr Issues Intest Microbiol. 2003; 4: 9–20.
3. Gibson GR, Roberfroid MB Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995; 125: 1401–1412.
4. Kanamori Y., Sugiyama M., Hashizume K., et al. Experience of long-term synbiotic therapy in seven short bowel patients with refractory enterocolitis. J Pediatr Surg. 2004; 39: 1686–1692.
5. Haskey N., Dahl WJ Synbiotic therapy: a promising new adjunctive therapy for ulcerative colitis. Nutr Rev. 2006; 64: 132–138.
6. Furrie E., Macfarlane S., Kennedy A., et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomized controlled trial. Gut. 2005; 54: 242–249.
7. Hyams JS, Davis P., Grancher K., et al. Clinical outcome of ulcerative colitis in children. J Pediatr. 1996; 129: 81–88.
8. Martin A., Leone L., Fries W., et al. Quality of life in inflammatory bowel disease. J Gastroenterol. 1995; 27: 450–454.
9. Irvine EJ, Zhou Q., Thompson AK The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol. 1996; 91: 1571–1578.
10. Jowett SL, Seal CJ, Barton JR, et al. The Short Inflammatory Bowel Disease Questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol. 2001; 96: 2921–2928.
11. Casellas F., Lopez-Vivancos J., Badia X., et al. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol. 2001; 13: 567–572.
12. Lewis S., Burmeister S., Cohen S., et al. Failure of dietary oligofructose to prevent antibiotic-associated diarrhea. Aliment Pharmacol Ther. 2005; 21: 469–477.
13. Picard C., Fioramonti J., Francois A., et al. Bifidobacteria as probiotic agents: physiological effects and clinical benefits. Aliment Pharmacol Ther. 2005; 22: 495–512.
14. Institut Rosell Research & Development internal results: Bifidobacterium longum Rosell-175 [brochure]. Montreal, Canada: Institut Rosell; 2002.
15. Penner RM, Fedorak RN Probiotics in the management of inflammatory bowel disease. MedGenMed. 2005; 7: 19.